Towards the Use of Instrumented Tests for Screening the Risk of Falling in Patients With Chronic Illness. (DETECACTI)
Primary Purpose
Joint Osteoarthritis, Atherosclerosis of the Distal Arteries, Without Gangrene, Parkinson Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.
Sponsored by
About this trial
This is an interventional diagnostic trial for Joint Osteoarthritis focused on measuring Inertial sensors, Timed Up and Go test, 6-Minute Walk test, Fall, Risk of fall, Altered mobility, Chronic illness, Chronic pathologies, Physical capacities, Physical test, Activity limitations
Eligibility Criteria
Inclusion Criteria:
- Man or woman aged 18 to 90.
- Patients with chronic pathology contributing to impaired mobility.
- Volunteers who have given their written consent.
- Affiliated to French health care system (for France)
Exclusion Criteria:
- Patients suffering from progressive psychiatric pathologies (active psychosis, hallucinations, etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.).
- People with poorly controlled or unstable cardiovascular disease.
- Major osteoarticular or neurological problems completely preventing the proper performance of the various tests.
- Persons under guardianship, curatorship, deprived of liberty or safeguarding justice.
- People refusing to participate.
- Pregnant or lactating women.
Sites / Locations
- Chu Clermont Ferrand
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Cohort 1 : experimental group
Arm Description
Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
Outcomes
Primary Outcome Measures
Vertical acceleration in m/s² during the sit to stand phase of the Timed-Up and Go test.
Vertical acceleration will be collected with the mTUG® inertial sensor unit.
Maximum voluntary isokinetic strength (Nm) of the quadriceps muscles in slow speed (60°/s) concentric contraction.
: Maximum voluntary isokinetic strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device.
Secondary Outcome Measures
Demographics information
Demographics information will be obtained using a single questionnaire including questions on age, gender, qualification, personal work status, ethnicity, life and occupational events.
Weight (Kg).
Weight will be measured with the medical body weight scale SECA® and according to the ISAK recommendations.
Height (cm).
Height will be measured with a wall mounted tape measure and according to the ISAK recommendations.
Waist circumference (cm).
Waist circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Hip circumference (cm).
Hip circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Brachial circumference (cm).
Brachial circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Calf circumference (cm).
Calf circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Body Mass Index (Kg/m²).
Description: BMI will be calculated (weight in kilograms divided by height in meters squared).
Body composition.
Body composition (muscle and fat) will be measured using he Bodystat® Impedance-meter.
Self-Reported Number of Falls during the previous year
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Self-Reported Number of Falls during the previous year
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Self-Reported Number of Falls during the previous year
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Sarcopenia risk.
Sarcopenia risk will be evaluated with the SARC-F Questionnaire.
Balance confidence in performing various activities
Self-report balance confidence will be evaluated with the Activities-specific Balance Confidence (ABC) Scale.
Maximum voluntary isometric strength of the quadriceps muscles at 45° (Nm).
: Maximum voluntary isometric strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s (Nm).
Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s (Nm).
Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s (eccentric contraction) (Nm).
Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s (Nm).
Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s (Nm).
Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s will be measured with the HUMA® /NORM™ device.
Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s (eccentric contraction) (Nm).
Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s will be measured with the HUMA® /NORM™ device.
Statokinesigram surface area (mm²).
Statokinesigram surface area will be measured with the STATIPRO® static posturography platform.
Stabilogram length (mm).
Stabilogram length will be measured with the STATIPRO® static posturography platform.
Maximal deflection (forward, backward left and right).
Maximal deflection will be measured with the STATIPRO® static posturography platform.
Velocity variations (mm/s).
Velocity variations will be measured with the STATIPRO® static posturography platform.
Romberg ratio according to sway area
Romberg ratio will be measured with the STATIPRO® static posturography platform
Romberg ratio according to center of pressure path length.
Romberg ratio will be measured with the STATIPRO® static posturography platform.
Plantar pressure ratio sway area.
: Plantar pressure ratio sway area will be measured with the STATIPRO® static posturography platform
Plantar pressure ratio length
Plantar pressure ratio length will be measured with the STATIPRO® static posturography platform.
Walking velocity (cm/s).
Walking velocity will be measured with the GAITRite® Electronic Walkway.
Cadence (steps/min).
Cadence will be measured with the GAITRite® Electronic Walkway.
Step length (left and right foot) (cm)
: Step length will be measured with the GAITRite® Electronic Walkway.
Stride length (cm).
Stride length will be measured with the GAITRite® Electronic Walkway.
: Single support time left and right foot (% of walking cycle)
Single support time will be measured with the GAITRite® Electronic Walkway.
Double support time (% of walking cycle).
Double support time will be measured with the GAITRite® Electronic Walkway.
Swing time (% of walking cycle).
: Swing time will be measured with the GAITRite® Electronic Walkway.
Swing phase (% of walking cycle).
Swing phase will be measured with the GAITRite® Electronic Walkway.
Stance phase (% of walking cycle).
: Stance phase will be measured with the GAITRite® Electronic Walkway.
Functional capacity Timed-Up and Go
Functional capacity will be evaluated using the Timed-Up and Go test.
Functional capacity TDM6
Functional capacity will be evaluated using the 6-minute walk test.
Vertical acceleration (m/s²) during the sit to stand phase of the Timed-Up and Go test (TUG).
Vertical acceleration will be measured with the mTUG® inertial sensor unit.
Time (s) to complete the Timed-Up and Go test.
Time will be measured with the mTUG® inertial sensor unit.
Anteroposterior acceleration (m/s2) during stand to walk phase of the Timed-Up and Go test
Anteroposterior acceleration will be measured with the mTUG® inertial sensor unit.
Vertical angular speed (m/s) during the TUG test.
Vertical angular speed will be measured with the mTUG® inertial sensor unit.
Medio-lateral angular velocity (m/s) during the TUG test.
Medio-lateral angular velocity (m/s) will be measured with the mTUG® inertial sensor unit.
Time (s) of the 180° rotation phase during the TUG test.
Time of the rotation phase will be measured with the mTUG® inertial sensor unit
Time (s) to pass from the sitting position to the first step during the TUG test.
Time will be measured with the mTUG® inertial sensor unit.
Duration (s) of the turn to sit phase during the TUG test.
Time will be measured with the mTUG® inertial sensor unit.
Total number of steps during the TUG test.
Steps will be measured with the mTUG® inertial sensor unit.
Average length of steps (m) during the TUG test.
Steps will be measured with the mTUG® inertial sensor unit.
Average walking speed (m/s) during the TUG test.
Walking speed will be measured with the mTUG® inertial sensor unit.
Number of steps during the 180° rotation phase of the TUG test.
Steps will be measured with the mTUG® inertial sensor unit.
Standard deviation of the duration of the step (s) during the TUG test.
Standard deviation will be measured with the mTUG® inertial sensor unit.
Spatio-temporal gait parameters (Average walking speed, step and stride length (right and left), cadence variability, variability in stride length, stance and swing phase, …) during the 6-minute Walk Test (6MWT).
Spatio-temporal gait parameters will be measured with the mGAIT® inertial unit sensors
Full Information
NCT ID
NCT04368858
First Posted
April 27, 2020
Last Updated
November 18, 2022
Sponsor
University Hospital, Clermont-Ferrand
1. Study Identification
Unique Protocol Identification Number
NCT04368858
Brief Title
Towards the Use of Instrumented Tests for Screening the Risk of Falling in Patients With Chronic Illness.
Acronym
DETECACTI
Official Title
Towards the Use of Instrumented Tests for Screening the Risk of Falling in Patients With Chronic Illness.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
August 28, 2020 (Actual)
Primary Completion Date
November 16, 2022 (Actual)
Study Completion Date
November 16, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Clermont-Ferrand
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In patients with chronic illness, screening for falls and their health consequences are major public health issues. Muscle weakness, gait and balance disorders are among the most common risk factors for falling. Assessing these parameters would thus be a crucial step in the evaluation of the risk of falling, allowing to more precisely orient the management strategy. Combining inertial unit sensors with clinically validated tests can provide additional information to improve the assessment of fall risks. We therefore propose to constitute a monocentric exploratory study, testing a prognostic screening tool, in patients suffering from a chronic pathology, in order to assess the risk of falling in this population.
Considering the relationship between muscle weakness and the risk of falling, we can assume that a deficit in muscle strength will result in less vertical acceleration which could point to a muscle cause of the balance disorder and thus allow a finer detection of the risk of falling. On the other hand, we hypothesize that spinal static disorders in chronic pathologies and in particular osteoarthritis, as well as balance disorders linked to impaired deep sensitivity lead to an increase in oscillations of the trunk when walking which can cause postural balance disorders thus increasing the risk of falling.
Detailed Description
Investigators propose to constitute a prospective cohort of subjects carrying chronic disease. The main objective is to study the correlation between the vertical acceleration during the sit to stand phase of the instrumented Timed Up and Go test (TUG) and the isokinetic muscle strength of the quadriceps. In addition, as secondary objectives, we will study the potential correlations between the other parameters collected with the inertial sensors during instrumented tests (Timed-Up and Go test, and 6-Minute Walk Test) and the isokinetic muscle strength of the lower limb muscles, posturography parameters, gait parameters, apprehension of fall and others.
In the present protocol, parameters will be measured once at inclusion day (to). Only the falling incidences will be collected prospectively at 6 months and at 1 year from the inclusion day.
Statistical analyses will be carried out using Stata software (version 13, StataCorp, College Station, USA). Qualitative variables will be described in terms of numbers and associated percentages. The quantitative variables will be described in terms of numbers, associated mean and standard deviation, median and interquartile range. Wherever is possible, graphic representations will be associated with these analyses. All tests will be performed for a bilateral hypothesis and a p-value <5% will be considered statistically significant. For the main outcome, the Pearson correlation coefficient (or Spearman if data are not normally distributed) will be calculated with its 95% confidence interval. The analysis of the relationships between the continuous criteria will be carried out using Pearson correlation coefficients (or Spearman if data are not normally distributed).
The search for fall risk factors (at 6 months / 1 year) will be carried out using standard tests:
Chi-square test (or exact Fisher test when appropriate) for the categorical criteria.
Student test (or Mann and Whitney test if data not normally distributed) for continuous criteria.
These analyses will be completed using a logistic regression model by adjusting to the clinically relevant criteria or highlighted in the univariate analysis. Results will be presented as an odd ratio with their 95% confidence interval
Little or no missing data is expected on the main criteria, however if a rate of missing data> 5% is observed, a sensitivity analysis for missing data will be carried out in order to characterize their nature (MCAR, MAR, MNAR) in order to propose the most suitable imputation method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Joint Osteoarthritis, Atherosclerosis of the Distal Arteries, Without Gangrene, Parkinson Disease, Chronic Obstructive Pulmonary Disease, Unspecified, Obesity, Unspecified
Keywords
Inertial sensors, Timed Up and Go test, 6-Minute Walk test, Fall, Risk of fall, Altered mobility, Chronic illness, Chronic pathologies, Physical capacities, Physical test, Activity limitations
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cohort 1 : experimental group
Arm Type
Experimental
Arm Description
Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
Intervention Type
Diagnostic Test
Intervention Name(s)
Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.
Intervention Description
In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
Primary Outcome Measure Information:
Title
Vertical acceleration in m/s² during the sit to stand phase of the Timed-Up and Go test.
Description
Vertical acceleration will be collected with the mTUG® inertial sensor unit.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength (Nm) of the quadriceps muscles in slow speed (60°/s) concentric contraction.
Description
: Maximum voluntary isokinetic strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Secondary Outcome Measure Information:
Title
Demographics information
Description
Demographics information will be obtained using a single questionnaire including questions on age, gender, qualification, personal work status, ethnicity, life and occupational events.
Time Frame
day 0
Title
Weight (Kg).
Description
Weight will be measured with the medical body weight scale SECA® and according to the ISAK recommendations.
Time Frame
day 0
Title
Height (cm).
Description
Height will be measured with a wall mounted tape measure and according to the ISAK recommendations.
Time Frame
day 0
Title
Waist circumference (cm).
Description
Waist circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Time Frame
day 0
Title
Hip circumference (cm).
Description
Hip circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Time Frame
day 0
Title
Brachial circumference (cm).
Description
Brachial circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Time Frame
day 0
Title
Calf circumference (cm).
Description
Calf circumference will be measured with a medical body tape measure and according to the ISAK recommendations.
Time Frame
day 0
Title
Body Mass Index (Kg/m²).
Description
Description: BMI will be calculated (weight in kilograms divided by height in meters squared).
Time Frame
day 0
Title
Body composition.
Description
Body composition (muscle and fat) will be measured using he Bodystat® Impedance-meter.
Time Frame
day 0
Title
Self-Reported Number of Falls during the previous year
Description
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Time Frame
day 0
Title
Self-Reported Number of Falls during the previous year
Description
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Time Frame
Month 6
Title
Self-Reported Number of Falls during the previous year
Description
Number of falls will be evaluated with the Elderly Fall Screening Test (EFST).
Time Frame
Year 1
Title
Sarcopenia risk.
Description
Sarcopenia risk will be evaluated with the SARC-F Questionnaire.
Time Frame
Day 0
Title
Balance confidence in performing various activities
Description
Self-report balance confidence will be evaluated with the Activities-specific Balance Confidence (ABC) Scale.
Time Frame
Day 0
Title
Maximum voluntary isometric strength of the quadriceps muscles at 45° (Nm).
Description
: Maximum voluntary isometric strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s (Nm).
Description
Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s (Nm).
Description
Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s (eccentric contraction) (Nm).
Description
Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s (Nm).
Description
Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s (Nm).
Description
Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s (eccentric contraction) (Nm).
Description
Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s will be measured with the HUMA® /NORM™ device.
Time Frame
Day 0
Title
Statokinesigram surface area (mm²).
Description
Statokinesigram surface area will be measured with the STATIPRO® static posturography platform.
Time Frame
Day 0
Title
Stabilogram length (mm).
Description
Stabilogram length will be measured with the STATIPRO® static posturography platform.
Time Frame
Day 0
Title
Maximal deflection (forward, backward left and right).
Description
Maximal deflection will be measured with the STATIPRO® static posturography platform.
Time Frame
Day 0
Title
Velocity variations (mm/s).
Description
Velocity variations will be measured with the STATIPRO® static posturography platform.
Time Frame
Day 0
Title
Romberg ratio according to sway area
Description
Romberg ratio will be measured with the STATIPRO® static posturography platform
Time Frame
day 0
Title
Romberg ratio according to center of pressure path length.
Description
Romberg ratio will be measured with the STATIPRO® static posturography platform.
Time Frame
day 0
Title
Plantar pressure ratio sway area.
Description
: Plantar pressure ratio sway area will be measured with the STATIPRO® static posturography platform
Time Frame
day 0
Title
Plantar pressure ratio length
Description
Plantar pressure ratio length will be measured with the STATIPRO® static posturography platform.
Time Frame
day 0
Title
Walking velocity (cm/s).
Description
Walking velocity will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Cadence (steps/min).
Description
Cadence will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Step length (left and right foot) (cm)
Description
: Step length will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Stride length (cm).
Description
Stride length will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
: Single support time left and right foot (% of walking cycle)
Description
Single support time will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Double support time (% of walking cycle).
Description
Double support time will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Swing time (% of walking cycle).
Description
: Swing time will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Swing phase (% of walking cycle).
Description
Swing phase will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Stance phase (% of walking cycle).
Description
: Stance phase will be measured with the GAITRite® Electronic Walkway.
Time Frame
day 0
Title
Functional capacity Timed-Up and Go
Description
Functional capacity will be evaluated using the Timed-Up and Go test.
Time Frame
day 0
Title
Functional capacity TDM6
Description
Functional capacity will be evaluated using the 6-minute walk test.
Time Frame
day 0
Title
Vertical acceleration (m/s²) during the sit to stand phase of the Timed-Up and Go test (TUG).
Description
Vertical acceleration will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Time (s) to complete the Timed-Up and Go test.
Description
Time will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Anteroposterior acceleration (m/s2) during stand to walk phase of the Timed-Up and Go test
Description
Anteroposterior acceleration will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Vertical angular speed (m/s) during the TUG test.
Description
Vertical angular speed will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Medio-lateral angular velocity (m/s) during the TUG test.
Description
Medio-lateral angular velocity (m/s) will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Time (s) of the 180° rotation phase during the TUG test.
Description
Time of the rotation phase will be measured with the mTUG® inertial sensor unit
Time Frame
day 0
Title
Time (s) to pass from the sitting position to the first step during the TUG test.
Description
Time will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Duration (s) of the turn to sit phase during the TUG test.
Description
Time will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Total number of steps during the TUG test.
Description
Steps will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Average length of steps (m) during the TUG test.
Description
Steps will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Average walking speed (m/s) during the TUG test.
Description
Walking speed will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Number of steps during the 180° rotation phase of the TUG test.
Description
Steps will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Standard deviation of the duration of the step (s) during the TUG test.
Description
Standard deviation will be measured with the mTUG® inertial sensor unit.
Time Frame
day 0
Title
Spatio-temporal gait parameters (Average walking speed, step and stride length (right and left), cadence variability, variability in stride length, stance and swing phase, …) during the 6-minute Walk Test (6MWT).
Description
Spatio-temporal gait parameters will be measured with the mGAIT® inertial unit sensors
Time Frame
day 0
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Man or woman aged 18 to 90.
Patients with chronic pathology contributing to impaired mobility.
Volunteers who have given their written consent.
Affiliated to French health care system (for France)
Exclusion Criteria:
Patients suffering from progressive psychiatric pathologies (active psychosis, hallucinations, etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.).
People with poorly controlled or unstable cardiovascular disease.
Major osteoarticular or neurological problems completely preventing the proper performance of the various tests.
Persons under guardianship, curatorship, deprived of liberty or safeguarding justice.
People refusing to participate.
Pregnant or lactating women.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emmanuel COUDEYRE
Organizational Affiliation
University Hospital, Clermont-Ferrand
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu Clermont Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
12. IPD Sharing Statement
Learn more about this trial
Towards the Use of Instrumented Tests for Screening the Risk of Falling in Patients With Chronic Illness.
We'll reach out to this number within 24 hrs